Výsledky vyhledávání - "GEJ adenocarcinoma"

Akademický článek

Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial

Autor: Maheswari Senthil, Farshid Dayyani

Publikováno v: BMC Cancer, Vol 23, Iss 1, Pp 1-7 (2023)

Abstract Background Studies from Asia indicate that normothermic intraperitoneal chemotherapy (NIPEC) may confer survival benefit in patients with gastric peritoneal carcinomatosis (PC). However, data regarding this approach is lacking in western pop

Externí odkaz: https://doaj.org/article/20d87ff5019e4f94b1e8b5929eb120a2

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis

Autor: Bo-Wei Liu, Qi-Xing Shang, Yu-Shang Yang, Long-Qi Chen

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

BackgroundThere is increasing evidence that immunotherapy (programmed cell death-1 (PD-1) inhibitor) combined with chemotherapy is superior to chemotherapy alone in neoadjuvant therapy for patients with previously untreated, unresectable advanced, or

Externí odkaz: https://doaj.org/article/66d37977573a48949e0997691a75e90a

Zobrazit plný text záznamu

Akademický článek

Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study

Autor: Zhichao Jiang, Aiping Zhou, Yongkun Sun, Wen Zhang

Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)

Abstract Background SOX (oxaliplatin and S1, every 3 weeks) is one of the most common first-line chemotherapy for advanced or metastatic G/GEJ (gastric or gastroesophageal junction) cancer in Asia, but it has noticeable hematological and neurological

Externí odkaz: https://doaj.org/article/7d9d1cd1529f4662ba3ead82e2198f9d

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study

Autor: Hirva Mamdani, Bryan Schneider, Susan M. Perkins, Heather N. Burney, Pashtoon Murtaza Kasi, Laith I. Abushahin, Thomas Birdas, Kenneth Kesler, Tracy M. Watkins, Sunil S. Badve, Milan Radovich, Shadia I. Jalal

Publikováno v: Frontiers in Oncology, Vol 11 (2021)

BackgroundMost patients with resectable locally advanced esophageal and gastroesophageal junction (GEJ) adenocarcinoma (AC) receive concurrent chemoradiation (CRT) followed by esophagectomy. The majority of patients do not achieve pathologic complete

Externí odkaz: https://doaj.org/article/f9a4664453e6418fabce1ca1942a0473

Zobrazit plný text záznamu

Akademický článek

Autophagic Heterogeneity in Gastric Adenocarcinoma

Autor: Ju-Yoon Yoon, Christine Brezden-Masley, Catherine J. Streutker

Publikováno v: Frontiers in Oncology, Vol 11 (2021)

Background and AimGastric/gastroesophageal junction (GEJ) adenocarcinoma is a heterogeneous disease, with various etiologies and with tumors encompassing a spectrum of histologic and molecular subtypes. “Autophagy” includes two related but distin

Externí odkaz: https://doaj.org/article/6035d8fa2d9b47b485666388b0acf436

Zobrazit plný text záznamu

Akademický článek

Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report

Autor: Giuseppe Tirino, Angelica Petrillo, Luca Pompella, Annalisa Pappalardo, Maria Maddalena Laterza, Iacopo Panarese, Rosalaura Sabetta, Renato Franco, Gennaro Galizia, Fortunato Ciardiello, Ferdinando De Vita

Publikováno v: Frontiers in Oncology, Vol 10 (2020)

Background: The prognosis of patients with advanced gastric cancer remains overall poor despite some recent innovations and the development of new therapeutic approaches. Current European guidelines do not recommend any specific treatment for patient

Externí odkaz: https://doaj.org/article/ddd0c27b93f94ae29c14ae225c7e716e

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase II Clinical trial of Sequential Treatment with Systemic Chemotherapy and Intraperitoneal Paclitaxel for Gastric and Gastroesophageal Junction Peritoneal Carcinomatosis - STOPGAP Trial

Autor: Senthil, Maheswari, Dayyani, Farshid

Publikováno v: BMC cancer, vol 23, iss 1

Background Studies from Asia indicate that normothermic intraperitoneal chemotherapy (NIPEC) may confer survival benefit in patients with gastric peritoneal carcinomatosis (PC). However, data regarding this approach is lacking in western population.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c601d3395ab9a1f6a1227b4e00f3e2f8
https://doi.org/10.21203/rs.3.rs-2347776/v1

Zobrazit plný text záznamu

Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study

Publikováno v: FUTURE ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, retrospective study carried out in 20 Spanish hospitals

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030a84cb2d8164ed6ed0b45b3e7668ff
https://pubmed.ncbi.nlm.nih.gov/33590772

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání